Side Effects

GLP-1 and Diarrhea: How Common Is It and What Helps

GLP-1 Companion · 7 min read

Among the gastrointestinal side effects of GLP-1 receptor agonists, diarrhea often surprises patients who expect primarily constipation or nausea. Yet loose stools and diarrhea affect approximately 15–20% of patients on GLP-1 therapy — making it one of the more prevalent early side effects. Understanding why it occurs, which medications are more likely to cause it, and how to manage it effectively can make the difference between pushing through a temporary side effect and unnecessarily stopping treatment.

How Common Is GLP-1-Related Diarrhea?

Clinical trial data shows diarrhea rates of approximately 15–20% across GLP-1 and dual GLP-1/GIP receptor agonist therapies. Importantly, tirzepatide (Mounjaro, Zepbound) — a dual GIP/GLP-1 agonist — consistently shows higher rates of diarrhea in clinical trials compared to semaglutide (Ozempic, Wegovy). In the SURMOUNT-1 trial, diarrhea was reported in approximately 17–22% of tirzepatide patients depending on dose, compared to lower rates in semaglutide trials. This likely reflects the additional GIP receptor agonism and its effects on intestinal motility and secretion.

The Mechanism: Why GLP-1 Causes Diarrhea

The mechanism of GLP-1-related diarrhea involves a paradox: the same medications that slow gastric emptying (the upper GI) can accelerate transit in the lower GI tract. This discordant motility effect is explained by the differential distribution of GLP-1 receptors along the gut. While the stomach slows down significantly, the colon may actually experience increased contractility and secretion.

Additionally, GLP-1 receptor activation alters gut hormone secretion — including peptide YY (PYY) and GLP-2 — which modulate fluid absorption and secretion in the intestines. When these hormonal signals shift, the intestinal lining may absorb less fluid from stool, resulting in looser, more frequent bowel movements. Changes in the gut microbiome composition, particularly during the dietary shifts that often accompany GLP-1 therapy, may further contribute.

When Diarrhea Is Most Likely to Occur

GLP-1-related diarrhea follows a predictable pattern: it is most frequent and most severe during dose titration — the first 2–4 weeks at each new dose level. As the body adapts to the current dose, diarrhea frequency typically decreases. Patients who experience diarrhea at one dose level often find it is much reduced or absent once they have been at that dose for 4–6 weeks. The pattern then repeats, usually more mildly, with each subsequent dose increase.

Managing Acute Diarrhea Episodes

Hydration and Electrolyte Replacement

Dehydration is the primary risk of GLP-1-related diarrhea and the most important thing to prevent. Each loose stool contains significant amounts of fluid and electrolytes — particularly sodium, potassium, and chloride. On GLP-1 therapy, where total fluid intake may already be reduced due to decreased appetite and nausea, the dehydrating effect of diarrhea is amplified. During episodes of diarrhea, prioritize:

• Drinking at minimum 8–10 cups of fluid per day — water, clear broth, diluted juice
• Oral rehydration solutions (Pedialyte, Liquid I.V., or homemade: 1 liter water + 6 tsp sugar + 0.5 tsp salt) — these replace both fluid and electrolytes more effectively than plain water
• Avoiding caffeinated beverages and alcohol, which worsen dehydration
• Recognizing signs of dehydration: dark concentrated urine, dizziness when standing, rapid heartbeat, dry mouth

The BRAT Diet

The BRAT diet — Bananas, Rice, Applesauce, and Toast — has long been used as a dietary approach for acute diarrhea. These foods are low in fiber, easy to digest, and help firm up loose stools. Bananas in particular provide potassium lost through diarrheal fluid. While the BRAT diet is nutritionally incomplete for prolonged use, it is an effective short-term (1–2 day) strategy during acute diarrhea episodes on GLP-1 therapy. Other appropriate foods include plain cooked potatoes, plain crackers, and boiled chicken.

Over-the-Counter Medications

Loperamide (Imodium) is the safest and most effective over-the-counter anti-diarrheal medication for GLP-1-related loose stools. It works by slowing intestinal motility and increasing water absorption from the stool. The standard adult dose is 4 mg initially followed by 2 mg after each subsequent loose stool, up to a maximum of 16 mg per day. Loperamide is appropriate for acute, self-limited GLP-1-related diarrhea. It should not be used if diarrhea is accompanied by fever or blood in the stool.

Psyllium fiber (Metamucil) may seem counterintuitive for diarrhea, but soluble fiber actually works in both directions — it absorbs excess water in loose stools and adds bulk, helping to normalize stool consistency. It is particularly useful for patients who experience alternating diarrhea and constipation (a pattern sometimes seen on GLP-1 therapy). Start with a low dose (1 teaspoon in 8 oz water) and ensure adequate water intake when using psyllium.

Long-Term Management Strategies

For patients who experience recurrent diarrhea with each dose escalation, the following approaches can reduce severity and duration:

1. Keep a food diary to identify dietary triggers — common culprits include high-fat meals, dairy, artificial sweeteners (sorbitol, mannitol), and very high-fiber foods
2. Reduce fat intake temporarily during dose escalation — fatty foods stimulate cholecystokinin release, which can accelerate intestinal transit
3. Consider requesting a slower dose escalation schedule from your provider — extending the time at each dose from 4 weeks to 6–8 weeks gives the gut more adaptation time
4. Probiotics — limited but growing evidence suggests Lactobacillus species may reduce GI side effects of GLP-1 therapy; a probiotic taken consistently during dose escalation may reduce diarrhea severity

When to Contact Your Doctor

Most GLP-1-related diarrhea is self-limiting and manageable at home. However, certain features warrant prompt medical evaluation:

• Diarrhea lasting more than 2 weeks at a stable dose with no improvement
• Bloody or black tarry stools — indicates GI bleeding
• High fever (above 38.5°C / 101.3°F) with diarrhea — raises concern for infectious cause
• Signs of severe dehydration: rapid heartbeat, fainting, inability to urinate
• Severe abdominal cramping accompanying diarrhea — must rule out more serious GI pathology
• Recent antibiotic use with new onset diarrhea — raises concern for Clostridioides difficile (C. diff) colitis

The Outlook: Does It Get Better?

The vast majority of patients find that GLP-1-related diarrhea significantly improves within 4–8 weeks at a stable dose. The gut adapts to the altered motility environment, the microbiome adjusts, and dietary patterns stabilize. For patients on tirzepatide who find diarrhea more persistent, discussing whether to slow the dose escalation schedule with their prescriber is a reasonable and effective option. Very few patients need to discontinue GLP-1 therapy due to diarrhea alone when it is actively managed.

Sources

• Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism.
• Ozempic (semaglutide) Prescribing Information. Novo Nordisk.